Jul 25, 2018

Mylan Launches New Self-administered HIV Detection Kit in Ireland

The new self-test kit from leading pharmaceutical company Mylan – autotest VIH® - can detect HIV antibodies in just 15 minutes and is now available over-the-counter in pharmacies across Ireland

  • The discreet and easy-to-use kit is available without a prescription to people over the age of 18;
  • HIV diagnoses in Ireland have increased significantly in the last decade – up 43.9% from 2006 to 2016 – according to HPSC data.

Dublin, Ireland – 25 July 2018 – Mylan, a leading global pharmaceutical company in Ireland, has today launched a new over-the-counter HIV self-testing kit that can detect the presence of the virus in the blood.

Commenting,Owen McKeon, Country Manager, Mylan Ireland, said:

"Mylan has a long history in the fight against HIV and AIDS. As one of the largest providers of antiretroviral solutions in the world, Mylan is supporting early testing and prevention in Ireland through the launch of our HIV self-test kit. In doing so, Ireland becomes our fourth market to launch in, following already successful launches in France, Italy and Spain. Over the coming months, we will be working with HIV patient organisations to increase awareness of the importance of early testing, and how tools like our self-testing kit, as well as taking a proactive approach to your health, can help in the fight against the spread of HIV."
The kit, autotest VIH®, is a medical device for home use, allowing those who want to self-test to do so quickly and discreetly.

  • To use autotest VIH®, the user takes a pinprick sample of their blood with the device.
  • The device then looks for the presence of HIV antibodies in the blood.
  • Accurate results (HIV+ or HIV-) are provided within 15 minutes.

Each HIV self-test kit comes with an information leaflet on how to use the test correctly and contact information for GOSHH (Gender, Orientation, Sexual Health and HIV) helpline. In case of an HIV positive result, users are advised to attend a full sexual health screening with their healthcare professional*.

Autotest VIH®is a third-generation self-test kit and as such, users are advised to wait three months from the point of potential exposure to HIV and testing. This window period is the time it takes for the body to produce antibodies that signal the presence of HIV**.

Those people living with HIV, but who are not aware of their status, could be unknowingly transmitting it to others – a reality that Mylan hopes to change.

HIV diagnoses in Ireland have increased within the last decade, particularly since 2011. There were 508 new diagnoses of HIV in Ireland in 2016, representing a 43.9% increase since 20061 . These latest HSE HPSC figures show that the infection predominantly afflicts men, with 48% of new diagnoses reflecting those aged 20-34 years old and 41% in the age range 35-49 years.

Ann Mason, Manager of GOSHH (Gender, Orientation, Sexual Health, and HIV),said:

"8,341 people have been diagnosed with HIV in Ireland since the early 1980s. Today, HIV is a treatable infection and the sooner someone living with HIV accesses treatment, the sooner the medication will reduce their viral load to undetectable. Whether you are HIV negative, positive or have never been tested, there are channels to discuss it. It is also important to encourage people to openly discuss their HIV Status with their sexual partner.
With discreet and easy-to-use tools like the Mylan self-test kit and with helplines like GOSHH to support their use, we hope to see more people avail of testing, an increased ability to manage symptoms early on, and ultimately, a decline in HIV diagnoses."


Note to editors
*Where a user has doubts or cannot interpret the results, it is recommended to consult the helpline provided and/or a medical professional.
** The autotest VIH® self-test kit is designed to detect HIV antibodies, but not other sexually transmitted infections or diseases.

Mylan's commitment to the treatment of HIV/AIDS

For more than a decade, Mylan has been a leader in providing access to quality, dependable and affordable ARVs in more than 100 countries around the world. This includes introducing in 2009 the first generic one-tablet-once-a-day combination for developing countries – only three years after the originator product launched in the U.S. Since that time, Mylan has been the first to market with nearly half of the new products approved under the FDA's PEPFAR program. Mylan was also the first generic drug maker to develop a heat-stable version of a drug critical for second-line regimens, and is the leading supplier of paediatric ARVs, including taste-masked and dispersible formulations. Mylan has also long been a supporter of the patient community through the sponsorship of free community HIV/AIDS testing and clinical research. Learn more about Mylan's work with infectious disease here. Watch this video to learn more about Mylan's commitment to people living with HIV/AIDS.

About Mylan

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what’s right, not what’s easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.

Mylan is one of the largest employers in pharmaceuticals in Ireland with four facilities in Dublin and a large campus in Inverin, Galway- with a total combined workforce of approximately 1,600 people.

1 http://www.hpsc.ie/a-z/hivstis/hivandaids/hivdataandreports/HIVIreland_2016.pdf

Last Updated:  25/07/2018